Page 15 - Vxrt News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Vxrt. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Vxrt Today - Breaking & Trending Today
Vaxart (NASDAQ:VXRT – Get Rating) and Surface Oncology (NASDAQ:SURF – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends. Risk & Volatility Vaxart has a beta of 0.67, indicating […] ....
Equities research analysts predict that Vaxart, Inc. (NASDAQ:VXRT – Get Rating) will post sales of $100,000.00 for the current fiscal quarter, Zacks Investment Research reports. Three analysts have made estimates for Vaxart’s earnings, with the lowest sales estimate coming in at $90,000.00 and the highest estimate coming in at $100,000.00. Vaxart reported sales of $110,000.00 […] ....
Wall Street brokerages predict that Vaxart, Inc. (NASDAQ:VXRT – Get Rating) will report ($0.20) earnings per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Vaxart’s earnings, with the highest EPS estimate coming in at ($0.19) and the lowest estimate coming in at ($0.22). Vaxart posted earnings per share […] ....
Vaxart (NASDAQ:VXRT – Get Rating) and Relay Therapeutics (NASDAQ:RLAY – Get Rating) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings. Volatility and Risk Vaxart has a beta of 0.41, indicating that […] ....
Vaxart (NASDAQ:VXRT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday, Zacks.com reports. According to Zacks, “Vaxart, Inc. is a clinical-stage company developing a range of oral recombinant vaccines based on its proprietary delivery platform. The […] ....